Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 18/20 | 0.80 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.80 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1377981 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6972308 | 0.83 | PTGS2 (1.00) | PTGS2PTGS1CA12CA1CA2 | |
| SCHEMBL6976478 | 0.83 | PTGS2 (0.72) | PTGS2PTGS1 | |
| SCHEMBL6975956 | 0.82 | PTGS2 (0.79) | PTGS2PTGS1MAOAMAOB | |
| SCHEMBL1376982 | 0.80 | PTGS2 (0.84) | PTGS2PTGS1 | |
| SCHEMBL6973887 | 0.78 | PTGS2 (0.80) | PTGS2PTGS1 | |
| SCHEMBL5708993 | 0.75 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL9261161 | 0.75 | PTGS2 (0.60) | PTGS2PTGS1 | |
| SCHEMBL6971292 | 0.75 | PTGS2 (0.65) | PTGS2PTGS1MAOAMAOBCA12 | |
| SCHEMBL6967436 | 0.74 | PTGS2 (0.77) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6518303-B2 | Selectively inhibit COX-2 in preference to COX-1 and are useful in the treatment of COX-2 mediated diseases, such as inflammation, pain, fever and asthma with fewer side effects | ALMIRALL PRODESFARMA S.A. (ES) | 2003-02-11 | — | — | US | disclosed |
| EP-1115716-B1 | 2-PHENYLPYRAN-4-ONE DERIVATIVES | ALMIRALL PRODESFARMA AG (CH) | 2003-01-02 | — | — | EP | disclosed |
| US-20020045644-A1 | 2-phenylpyran-4-one derivatives | LABORATORIES ALMIRALL, S.A. (ES) | 2002-04-18 | — | — | US | disclosed |
| EP-1115716-A1 | 2-PHENYLPYRAN-4-ONE DERIVATIVES | Almirall Prodesfarma, S.A. (ES) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018753-A1 | 2-PHENYLPYRAN-4-ONE DERIVATIVES | ALMIRALL PRODESFARMA, S.A. (ES) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045644-A1 | 2-phenylpyran-4-one derivatives | NR4A1, CYP3A4, HTR4 | PTGS2 912/4885PTGS1 451/4885MAOA 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.